The main objective is to develop a stable Formulation of Ramipril and Amlodipine in fixed dose Combination throughout the designed Shelf life. The fixed dose combination is useful in reducing Hypertension, cardiac failure, particularly in diabetic patients. Ramipril acts by inhibiting Angiotensin converting enzyme and Amlodipine acts by blocking the calcium channels. The combination of the two classes of drugs produce Synergistic action and better management of hypertension both in geriatric patients and patients suffering from diabetes. The present work involves the development of the stable formulation using the compatible Excipients and exposing the samples to Accelerated stability conditions thus predicting the shelf life. Totally RACS-001,RACS-002,RACS-003,RACS-004,RACS-005 trial batches are prepared and evaluated for Bulk density, Tapped density, Weight variation, Disintegration time, and Content uniformity, Assay and Evaluation for Dissolution profile and found all the parameters are within the specifications. © 2009 by Sudarshan Publication Sudarshan Institute of Technical Education Pvt. Ltd. © 2011 Elsevier B.V., All rights reserved.